Background: An increased frequency of psychotic disorders in amyotrophic lateral sclerosis (ALS) families compared to controls has been reported. Aim of our study was to assess the relationship between nervous system drugs prescriptions and subsequent onset of ALS in a large Italian population. Methods: The study population consisted of all subjects over 15 years at the 2001 Italian census, resident in Turin since 1996 (n = 687,324), followed up for ALS occurrence from 2002 to 2014. Exposure to nervous system drugs was measured until 2012, or until 1 year before ALS onset. The association was estimated for ever and cumulative exposure, through Cox proportional Hazards models adjusted for sex, age, education, marital status and drug co-exposure. Results: In the analysis for ever exposure, opioids were significantly inversely associated with ALS risk (hazard ratio (HR) 0.59; 95% CI 0.35-0.97), while antiepileptics (HR 1.35; 95% CI 0.92-2.00) showed a marginally significantly positive association. Examining cumulative exposure, the protective role of opioids associated with more than 4 prescriptions and the risk effect of antiepileptics for over 6 prescriptions was confirmed. Conclusions: The present study revealed associations of ALS onset with previous exposure to opioids, maybe through the activation of δ receptor and σ receptors and antiepileptics, which are novel findings to our knowledge.

1.
Al-Chalabi A, Hardiman O: The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617-628.
2.
Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA: Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118-130.
3.
Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E; EURALS: Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81:385-390.
4.
Renton AE, Chiò A, Traynor BJ: State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17-23.
5.
Ajroud-Driss S, Siddique T: Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 2015;1852:679-684.
6.
Cetin H, Klickovic U, Rath J, Zulehner G, Füzi J, Reichardt B, Hagmann M, Wanschitz J, Löscher WN, Auff E, Zimprich F: Associations between co-medications and survival in ALS - a cohort study from Austria. J Neurol 2015;262:1698-1705.
7.
Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM: Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007;8:157-163.
8.
Fondell E, O'Reilly EJ, Fitzgerald KC, Falcone GJ, McCullough ML, Thun MJ, Park Y, Kolonel LN, Ascherio A: Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler 2012;13:573-579.
9.
Tsai CP, Lin FC, Lee JK, Lee CT: Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study. J Epidemiol 2015;25:172-177.
10.
Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi Lee C: Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 2015;72:40-48.
11.
Fallis BA, Hardiman O: Aggregation of neurodegenerative disease in ALS kindreds. Amyotroph Lateral Scler 2009;10:95-98.
12.
Byrne S, Heverin M, Elamin M, Bede P, Lynch C, Kenna K, MacLaughlin R, Walsh C, Al Chalabi A, Hardiman O: Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol 2013;74:699-708.
13.
Hall D, Finger EC: Psychotic symptoms in frontotemporal dementia. Curr Neurol Neurosci Rep 2015;15:46.
14.
Galimberti D, Dell'Osso B, Altamura AC, Scarpini E: Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. Biol Psychiatry 2015;78:684-692.
15.
Stommel EW, Graber D, Montanye J, Cohen JA, Harris BT: Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis? Med Hypotheses 2007;69:1021-1028.
16.
Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R; PARALS: Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009;72:725-731.
17.
WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC Classification and DDD Assignment. Oslo, WHO Collaborating Centre for Drug Statistics, 2004.
18.
Sistema Statistico Nazionale - SISTAN: Piano di attuazione per l'anno 2014 del Programma statistico nazionale 2014-2016. http://www.sistan.it/fileadmin/Repository/Home/PSN/Piano_di_attuazione/Pda_2014.pdf (accessed February 22, 2016).
19.
Körner S, Kollewe K, Ilsemann J, Müller-Heine A, Dengler R, Krampfl K, Petri S: Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol 2013;20:647-654.
20.
Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED: Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
21.
Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, Hamasaki T, Goto M, Sakoda S: Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004;20:3179-3183.
22.
Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R; Western ALS Study Group: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
23.
Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, Schelhaas HJ, Scheffer H, de Visser M, de Jong JM, Wokke JH, Groeneveld GJ, van den Berg LH: Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009;66:227-234.
24.
Newrick PG, Langton-Hewer R: Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1985;48:838-840.
25.
Mitsumoto H: Diagnosis and progression of ALS. Neurology 1997;48(suppl 4):S2-S8.
26.
Stephens HE, Lehman E, Raheja D, Yang C, Walsh S, Simmons Z: The role of mental health and self-efficacy in the pain experience of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:206-212.
27.
Liang J, Chao D, Sandhu HK, Yu Y, Zhang L, Balboni G, Kim DH, Xia Y: δ-Opioid receptors up-regulate excitatory amino acid transporters in mouse astrocytes. Br J Pharmacol 2014;171:5417-5430.
28.
Mancuso R, Oliván S, Rando A, Casas C, Osta R, Navarro X: Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics 2012;9:814-826.
29.
Nguyen L, Kaushal N, Robson MJ, Matsumoto RR: Sigma receptors as potential therapeutic targets for neuroprotection. Eur J Pharmacol 2014;743:42-47.
30.
Mavlyutov TA, Guo LW, Epstein ML, Ruoho AE: Role of the sigma-1 receptor in amyotrophic lateral sclerosis (ALS). J Pharmacol Sci 2015;127:10-16.
31.
Pisa FE, Logroscino G, Casetta A, Cecotti L, Verriello L, Bratina A, Sartori A, Lazzarino de Lorenzo L, Eleopra R, Barbone F: The use of antidepressant medication before and after the diagnosis of amyotrophic lateral sclerosis: a population-based cohort study. Neuroepidemiology 2015;44:91-98.
32.
Armon C: Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009;73:1693-1698.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.